

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.1 Revision Date: 30.09.2023 SDS Number: 636527-00020 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable


SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 1A

Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Ovary)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Ovary) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.1 Revision Date: 30.09.2023 SDS Number: 636527-00020 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Classification | Concentration (% w/w) |
|-----------------------------------|-----------|--|-----------------------|
| Gonadotropin, pregnant mare serum | 9002-70-4 | Reproductive toxicity, Category 1B | >= 1 -< 5 |
| Gonadotropin, chorionic | 9002-61-3 | Reproductive toxicity, Category 1A Specific target organ toxicity - repeated exposure (Ovary), Category 1 | >= 1 -< 5 |

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : May damage fertility. Suspected of damaging the unborn child.

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 8.1 | Revision Date: 30.09.2023 | SDS Number: 636527-00020 | Date of last issue: 04.04.2023 Date of first issue: 03.05.2016 |
|----------------|------------------------------|-----------------------------|---|

| | |
|----------------------------|--|
| delayed | Causes damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. |
| Protection of first-aiders | : Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

| | |
|--|---|
| Suitable extinguishing media | : Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire fighting | : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides Nitrogen oxides (NO _x) Sulfur oxides Metal oxides Oxides of phosphorus |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for fire-fighters | : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| | |
|---|---|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). |

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. |
| Conditions for safe storage | : | Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases |

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.1 Revision Date: 30.09.2023 SDS Number: 636527-00020 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|-----------------------------------|-----------|-------------------------------|--|----------|
| Gonadotropin, pregnant mare serum | 9002-70-4 | TWA | 4 µg/m ³ (OEB 4) | Internal |
| | | Wipe limit | 40 µg/100 cm ² | Internal |
| Gonadotropin, chorionic | 9002-61-3 | TWA | OEB 4 (3 µg/m ³) | Internal |
| | | Wipe limit | 25 µg/100 cm ² | Internal |

Engineering measures : Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!
For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.1 Revision Date: 30.09.2023 SDS Number: 636527-00020 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

| | | |
|--|---|---|
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapor pressure | : | Not applicable |
| Relative vapor density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Autoignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity Viscosity, dynamic | : | No data available |
| Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

| | | |
|---|---|--|
| Acute oral toxicity | : | LD50 (Mouse): 120 mg/kg |
| Acute inhalation toxicity | : | Remarks: No data available |
| Acute dermal toxicity | : | Remarks: No data available |
| Acute toxicity (other routes of administration) | : | LD50 (Mouse): > 1.700 mg/kg Application Route: Intravenous |
| | | LD50 (Mouse): > 1.700 mg/kg Application Route: Subcutaneous |
| | | LD50 (Rat): 500 mg/kg Application Route: Intravenous |
| | | LD50 (Rat): 500 mg/kg Application Route: Subcutaneous |

Skin corrosion/irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

Version 8.1 Revision Date: 30.09.2023 SDS Number: 636527-00020 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Genotoxicity in vivo : Test Type: Cytogenetic assay
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive
Remarks: Not classified due to data which are conclusive although insufficient for classification.

Carcinogenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Carcinogenicity - Assessment : No data available

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Gonadotropin, pregnant mare serum:

Effects on fertility : Test Type: Fertility

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 8.1 | Revision Date: 30.09.2023 | SDS Number: 636527-00020 | Date of last issue: 04.04.2023 Date of first issue: 03.05.2016 |
|----------------|------------------------------|-----------------------------|---|

- Species: Rat
Application Route: Subcutaneous
Fertility: LOAEL: 10 µg/kg
Result: Effects on fertility.
Remarks: May cause adverse reproductive effects.
Based on data from similar materials
- Effects on fetal development : Remarks: May cause birth defects.
Based on data from similar materials
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.
- Gonadotropin, chorionic:**
- Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Intravenous injection
Fertility: LOAEL: 8,89 mg/kg body weight
Result: Effects on fertility.
- Test Type: Fertility
Application Route: Intraperitoneal injection
Fertility: LOAEL: 0,883 mg/kg body weight
Result: Effects on fertility.
- Test Type: Fertility
Species: Monkey
Fertility: LOAEL: 0,224 mg/kg body weight
Result: Effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development
Species: Hamster
Application Route: Intraperitoneal injection
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight
Result: Embryo-fetal toxicity.
- Reproductive toxicity - Assessment : Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Ovary) through prolonged or repeated exposure if swallowed.

Components:

Gonadotropin, chorionic:

- Target Organs : Ovary
Assessment : Causes damage to organs through prolonged or repeated

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

exposure.

Repeated dose toxicity

Components:

Gonadotropin, pregnant mare serum:

| | | |
|-------------------|---|---------------------|
| Species | : | Rat |
| NOAEL | : | 1,5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Days |
| Symptoms | : | No adverse effects. |

| | | |
|-------------------|---|---------------------|
| Species | : | Rat |
| LOAEL | : | 10 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 14 Days |
| Target Organs | : | Reproductive organs |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gonadotropin, pregnant mare serum:

| | | |
|--------------|---|---|
| Inhalation | : | Symptoms: Headache, Fatigue, mood swings, altered mental status, Edema, Allergic reactions, Effects on fertility. |
| Skin contact | : | Remarks: May produce an allergic reaction. |
| Ingestion | : | Remarks: May be harmful if swallowed. |

Gonadotropin, chorionic:

| | | |
|------------|---|---|
| Inhalation | : | Target Organs: ovaries Symptoms: effects on menstruation, gynecomastia, Headache, mental depression, Irritability, restlessness, Fatigue |
|------------|---|---|

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

Revision Date : 30.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Human Gonadotropin Chorionic / Serum Gonadotropin Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 8.1 | 30.09.2023 | 636527-00020 | Date of first issue: 03.05.2016 |

BR / Z8